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Abstract Protein tyrosine phosphatase-basophil like (PTP-BL)
is a large non-transmembrane protein tyrosine phosphatase
implicated in the modulation of the cytoskeleton. Here we
describe a novel interaction of PTP-BL with the protein kinase
C-related kinase 2 (PRK2), a serine/threonine kinase regulated
by the G-protein rho. This interaction is mediated by the PSD-
95, Drosophila discs large, zonula occludens (PDZ)3 domain of
PTP-BL and the extreme C-terminus of PRK2 as shown by
yeast two-hybrid assays and coimmunoprecipitation experiments
from transfected HeLa cells. In particular, we demonstrate that a
conserved C-terminal cysteine of PRK2 is indispensable for the
interaction with PTP-BL. In HeLa cells we demonstrate
colocalization of both proteins in lamellipodia like structures.
Interaction of PTP-BL with the rho effector kinase PRK2 gives
further evidence for a possible function of PTP-BL in the
regulation of the actin cytoskeleton. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Protein tyrosine phosphatase-basophil like (PTP-BL), its
human homologs are also known as PTPl1 [1], hPTP1e [2],
FAP-1 [3], and PTP-BAS [4], is a large non-transmembrane
protein tyrosine phosphatase. This phosphatase is structured
into functional modules consisting of an N-terminal four
point one, ezrin, radixin, moesin (FERM) domain followed
by ¢ve di¡erent PSD-95, Drosophila discs large, zonula occlu-
dens (PDZ) domains and a C-terminal located catalytic do-
main. A number of proteins have been described to interact
with one or two of the ¢ve PDZ domains of PTP-BL. The
IkappaBK protein [5] and the bromodomain protein BP75 [6]
interact with PDZ1, Fas [3], the zyxin family member ZRP-1/
TRIP6 [7,8] and the tumor suppressor protein APC [9] inter-
act with PDZ2, ephrinB [10], the rho GTPase activating pro-
tein (GAP) PARG [11] interact with PDZ4, and the protein
RIL is able to interact with PDZ2 and PDZ4 [12]. However,
to date no interacting proteins for PDZ3 and PDZ5 have been
described.
Here we describe that the protein kinase C-related kinase
(PRK)2 interacts selectively with the PDZ3 domain of PTP-
BL. This interaction depends on the last three amino acids of
PRK2. Moreover, in contrast to many other known binding
sequences for PDZ domains, a C-terminal cysteine is indis-
pensable for this interaction establishing a novel binding motif
for PDZ domains.
2. Materials and methods
2.1. Plasmids and antibodies
Full-length PRK2 was cloned from the clone isolated by two-hybrid
screening. The missing part of PRK2 was ampli¢ed from an expressed
sequence tag clone (M045304) using primers PAKC (5P-GATGG-
TACCGTCCATACCGGAGCGCAATG) and PAKD (5P-ACTCGT-
TTGCTCATGAAAGATG) (fragment I). Full-length PRK2 was gen-
erated using fragment I and a BamHI/EcoRI restriction fragment
from pGBT9 containing the cDNA of PRK2 isolated by two-hybrid
screening in a SOE (splicing by overlapping ends) PCR using primers
PAKC and PAKB (5P-TAGGGATCCGCTGAAGTACAATGAGG-
AGCCAC). Full-length PRK2 was subcloned using KpnI and BamHI
sites into pcDNA3. To increase expression of PRK2 the 3P-untrans-
lated region was shortened by exchanging a BstEII/BamHI fragment
with a corresponding PCR fragment ending with the translational
stop codon (primers PAKB and PAKT (TAGGGATCCTTAACAC-
CAATCAGCAATGTAGTC)). K/R mutant was generated by SOE-
PCR using mutant primers PAKK (5P-AGATGTTTGCTATAAGA-
GCCTTAAAGAAAGGAGATATTG) and PAKL (5P-CCTTTCTT-
TAAGGCTCTTATAGCAAACATCTCATTTGTG-3P). The PRK2
construct lacking the last three amino acids was generated by replac-
ing a BstEII/BamHI fragment with the corresponding PCR fragment
using primers PAKA (5P-GATGAATTCCCAACACTAAGTCCAC-
GGTCAAAG-3P) and PAKU (5P-TAGGGATCCTTAAGCAATGT-
AGTCAAAATCTCTG-3P), similar the C/S mutation was introduced
by replacing a BstEII/BamHI fragment with a PCR fragment using
primers PAKA and PAKR (5P-TAGGGATCCTTAAGACCAATCA-
GCAATGTAGTCAAAATC-3P). All constructs were subcloned into
pTRE2 (Clontech).
The coding region of each PDZ domain was ampli¢ed by PCR
from plasmid pcDNA3-PTP-BL and subcloned into pGEX2-T (Amer-
sham Pharmacia Biotech). PDZ1^5 was ampli¢ed from pcDNA3-
PTP-BL and subcloned in frame into pcDNA3 encoding for enhanced
green £uorescence protein (EGFP), generating an N-terminal EGFP
tagged PDZ1^5 fragment. Monoclonal anti-PRK2 antibody was pur-
chased from Transduction Laboratories, anti-PTP-BL has been de-
scribed before [9].
2.2. Yeast two-hybrid system
Yeast strain Hf7c (Clontech) was transformed sequentially with
pGBT9-PDZ1^5 coding for PDZ1 to PDZ5 of PTP-BL and a HeLa
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cDNA library (Clontech). Cotransformants were selected on minimal
agar plates lacking leucine, tryptophan and histidine. For L-galacto-
sidase assays, cotransformants were plated on plates lacking leucine
and tryptophan, ¢lter-lifts were performed and incubated with 560
Wg/ml 5-bromo-4-chloro-3-indolyl-L-D-galactopyranoside (X-Gal).
For identi¢cation of the interacting PDZ domain and for character-
izing the binding region in PRK2, Hf7c cells were simultaneously
transformed with the indicated expression constructs. Interaction
was determined by replating on minimal plates lacking leucine, tryp-
tophan and histidine. L-Galactosidase assay was performed as de-
scribed above.
2.3. Transient expression, pull-down assay and immunoprecipitation
Transfection of HeLa cells was performed using Polyfect (Qiagen)
according to the instructions of the manufacturer. HeLa cells were
transfected with expression vectors for the indicated PRK2 constructs.
48 h after transfection cells were lysed in lysis bu¡er (50 mM Tris^
HCl pH 7.4, 1 mM EDTA, 1% Triton X-100, 50 mM sodium £uoride,
0.27 M sucrose, 0.1% L-mercaptoethanol, 1Ucomplete protease inhib-
itor cocktail (Roche)). After centrifugation at 20 000Ug for 30 min
the supernatant was divided into ¢ve equal parts and incubated with
5 Wg glutathione-S-transferase (GST)-PDZ domain fusion protein
bound to glutathione-Sepharose beads. After incubation at 4‡C for
3 h, beads were collected by centrifugation and washed four times
with lysis bu¡er. Bound proteins were eluted with 1ULaemmli bu¡er
and separated on a 8% sodium dodecyl sulfate (SDS)^polyacrylamide
gel. Proteins were transferred to nitrocellulose and probed with an
anti-PRK2 antibody. Blots were developed using the ECL system
(Pharmacia Amersham Biotech). For coimmunoprecipitation experi-
ments, HeLa cells were cotransfected with an expression vector for
PDZ1^5-EGFP and the indicated PRK2 expression construct. Lysates
were prepared as described above. Equal amounts of lysate were in-
cubated with 4 Wg of anti-PRK2 antibody and incubated at 4‡C for 1 h
with rotation. After addition of 50 Wl protein A-Sepharose the in-
cubation was prolonged for an additional 3 h. Sepharose beads
were collected by centrifugation, and bound proteins were processed
as described above.
2.4. Immunocytochemistry
HeLa cells were ¢xed with 4% paraformaldehyde containing 4%
sucrose for 15 min on ice. After incubation with 0.25% Triton
X-100 in PBS (65 mM NaCl, 2.5 mM KCl, 1.2 mM NaHCO3,
2 mM KHCO3, pH 7.4) for 15 min, cells were washed extensively
with PBS. Unspeci¢c binding was blocked by 0.5% bovine serum
albumin in PBS/0.1% Triton X-100 for 15 min at room temperature.
Cells were incubated for 1 h with a⁄nity puri¢ed anti-PRK2 (1:30)
and anti-PTP-BL (1:30) antibody. First antibodies were detected us-
ing an ALEXA488 (Molecular Probes) conjugated anti-rabbit or a
Cy3 conjugated anti-mouse antibody. After each incubation the cov-
erslips were washed four times for 8 min with PBS. The coverslips
were mounted using Immuno£or (ICN Biomedicals) to prevent
bleaching.
3. Results
3.1. PRK2 interacts selectively with the PDZ3 domain of
PTP-BL
To identify new interacting proteins for the protein tyrosine
phosphatase PTP-BL, we applied the yeast two-hybrid system.
Using all ¢ve PDZ domains as a bait, we screened a HeLa
cDNA library. Among a number of positive clones one clone
encoded part of the protein kinase PRK2 [13]. We decided to
analyze this interaction in more detail, because PTP-BL is
implicated in the modulation of the cytoskeleton and PRK2
is a known rho e¡ector kinase possibly involved in the mod-
ulation of the actin cytoskeleton [14,15]. First we identi¢ed the
interacting PDZ domain of PTP-BL. Each PDZ domain was
subcloned into the yeast expression vector pGADGH and
tested for interaction with PRK2 by cotransformation into
yeast. There was only interaction detectable with the PDZ3
domain, indicated by histidine prototrophy and L-galactosi-
dase activity (Fig. 1A). To establish additional evidence for
this interaction, we performed pull-down experiments from
lysates of HeLa cells transfected with an expression vector
for full-length PRK2. Using fusion proteins of each PDZ
domain fused to GST, we observed only coprecipitation of
PRK2 with the GST-PDZ3 fusion protein (Fig. 1B).
3.2. The C-terminus of PRK2 is essential for interaction with
PTP-BL
Next we mapped the region in PRK2 responsible for bind-
ing to PDZ3 of PTP-BL. PRK2 consists of an N-terminal rho
binding site (hr1a, hr1b, hr1c), a C2 domain, involved in lipid
Fig. 1. PRK2 interacts selectively with the PDZ3 domain of PTP-
BL. A: HF7c cells were cotransformed with an expression construct
for PRK2 (amino acids 301^984) and for the PDZ domains of PTP-
BL. Interaction was monitored by histidine prototrophy and L-ga-
lactosidase activity. B: HeLa cells were transiently transfected with
an expression vector for full-length PRK2, cells were lysed and
equal amounts of lysates were incubated with the indicated GST
PDZ domain fusion proteins immobilized on glutathione-Sepharose.
Bound proteins were separated by SDS^PAGE and transferred to
nitrocellulose. The blot was developed using an anti-PRK2 anti-
body.
Fig. 2. The C-terminus of PRK2 is necessary for interaction with
PTP-BL. HF7c cells were cotransformed with expression vectors for
PDZ1^5 of PTP-BL and the indicated fragments of PRK2 sub-
cloned into pGADGH. Interaction is indicated by histidine proto-
trophy and L-galactosidase activity.
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binding and a kinase domain followed by a short C-terminal
tail. PRK2 was divided into three fragments corresponding to
these domains and tested for interaction with a construct en-
coding PDZ1 to PDZ5 (PDZ1^5) in the yeast two-hybrid
system. Only fragment III containing the kinase domain and
the C-terminus of the protein was able to interact with PDZ1^
5 (Fig. 2). To analyze this interaction with respect to the
phosphorylation status of PRK2 we performed a point muta-
tion K686 to R described to reduce the autophosphorylation
of PRK1, a close related family member of PRK2 [16]. In
addition we deleted the last three amino acids in construct
III. Point mutation of K to R did not alter binding of
PRK2 to PDZ1^5, but deletion of the last three amino acids
lead to a complete abolishment of the interaction. Moreover,
mutation of the C-terminal cysteine to serine in fragment III
was su⁄cient to disrupt the interaction completely (Fig. 2). To
prove these results independent from the two-hybrid system,
we generated full-length PRK2 mutants corresponding to our
two-hybrid constructs. Lysates of HeLa cells cotransfected
with expression vectors for PRK2 mutants and PDZ1^5-
EGFP were subjected to immunoprecipitation using a mono-
clonal antibody to PRK2. Immunoprecipitates were separated
on SDS^polyacrylamide gels, transferred to nitrocellulose and
probed with an antibody recognizing PDZ1^5. In line with
our two-hybrid assays only wild-type PRK2 or PRK2 K/R
was able to precipitate PDZ1^5 but not PRK2 devoid of the
last three amino acids or carrying a mutation in the C-termi-
nal cysteine (C/S) (Fig. 3A). Using expressed sequence tags
(ESTs) from di¡erent species we compared the amino acid
sequences of the C-termini of PRK2 homologs and deduced
the consensus sequence -YX(D/E)WC showing, that the C-
terminal cysteine is absolutely conserved (Fig. 3B).
3.3. PRK2 and PTP-BL colocalize in HeLa cells
To give a ¢rst evidence for a possible physiological rele-
vance of the interaction, we performed double immunocyto-
chemistry on cultured HeLa cells. We observed strong colo-
calization of both proteins in lamellipodia like structures and
the nuclei of the cells (Fig. 4).
In conclusion we demonstrate a speci¢c interaction of the
serine/threonine kinase PRK2 with the third PDZ domain of
PTP-BL. This interaction depends on the C-terminus of
PRK2, which contains an unusual PDZ binding motif with
an invariable C-terminal cysteine.
4. Discussion
Here we describe a novel interaction of the rho e¡ector
kinase PRK2 with the PDZ3 domain of PTP-BL. This inter-
action is highly speci¢c since no interaction could be detected
with the other four PDZ domains of PTP-BL as demonstrated
by yeast two-hybrid analysis and pull-down experiments using
the respective GST-PDZ domain fusion proteins. Moreover,
the interaction depends on the presence of a C-terminal cys-
teine in PRK2. Deletion of the last three amino acids or a
conservative exchange of the C-terminal cysteine to serine
Fig. 3. Coimmunoprecipitation of PRK2 and PDZ1^5 from trans-
fected HeLa cells. A: HeLa cells were transiently transfected with
expression vectors for the indicated PRK2 constructs (wt, wild-type;
del, deletion of the last three amino acids; C/S, exchange of the
C-terminal cysteine to serine) and PDZ1^5-EGFP. Cells were lysed
and lysates were subjected to immunoprecipitation using anti-PRK2
antibody. Bound proteins were separated by SDS^PAGE and trans-
ferred to nitrocellulose. The blot was developed using anti-PTP-BL
antibody, the blot was stripped and redetected using anti-PRK2
antibody. B: Comparison of the C-termini of PRK2 homologs of
the indicated species and deduced consensus sequence; for compari-
son the following expressed sequence tags (ESTs) were used: Rattus
norvegicus, BF404373, Gallus gallus, AJ395750, Drosophila mela-
nogaster AA699065, human full-length cDNA of PRK2, U33052.
Fig. 4. Colocalization of PRK2 and PTP-BL in HeLa cells. HeLa cells were stained for endogenous hPTP-BL (green) and PRK2 (red), the in-
sert shows an enlarged region of prominent colocalization, bar = 10 Wm.
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leads to a complete abolishment of the interaction. Interest-
ingly, a comparison of the C-termini of PRK2 homologs from
di¡erent species indicates a strong conservation of the last
four amino acids including the C-terminal cysteine suggesting
an important role in PRK2 function. Previously characterized
PDZ domains show a preference for large hydrophobic amino
acids like valine, leucine or isoleucine in the C-terminal posi-
tion (position 0) [17]. Explanation for this speci¢city was giv-
en by the existence of a hydrophobic pocket within the PDZ
domain, which can only be ¢lled in an energetically favored
way by large hydrophobic amino acids [18^20]. However, the
necessity of a C-terminal cysteine in position 0 as described
here for the PRK2/PTP-BL interaction suggests an additional
selection mechanism of PDZ domains for the last amino acid
of bound peptides. Interestingly Borrell-Pages et al. described
recently an invariable C-terminal cysteine for binding of the
L6A protein to the PDZ domain of SITAC (similar to TAC-
IP18) [21], however they identi¢ed a C-terminal consensus
sequence -Y-X-C-COOH essential for binding, which di¡ers
to ours in 32 position, where PRK2 shows conservation of an
acidic amino acid. Our ¢nding suggests that there are multiple
consensus binding sequences ending with an invariable C-ter-
minal cysteine indicating that this might be a more general
mode of peptide/PDZ domain interaction.
The physiological relevance of the interaction between
PRK2 and PTP-BL is underlined by their colocalization in
lamellipodia like structures in HeLa cells. These structures
are known to be regions of large actin turnover. Moreover,
this interaction is intriguing with respect to a possible function
of PTP-BL. PTP-BL interacts via its PDZ4 domain with the
rhoGAP PARG [11]; we demonstrate that the adjacent PDZ
domain interacts with the rho e¡ector PRK2. Thus, PTP-BL
might function as a sca¡old for proteins involved in rho/rac
signal transduction and thereby regulating the cytoskeleton.
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